Loading...

Keymed Biosciences Inc.

2162.HKHKSE
Healthcare
Biotechnology
HK$61.55
HK$0.15(0.24%)

Keymed Biosciences Inc. (2162.HK) Stock Competitors & Peer Comparison

See (2162.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2162.HKHK$61.55+0.24%18.1B-28.50-HK$2.16N/A
1801.HKHK$93.00-5.10%159B-1328.57-HK$0.07N/A
9926.HKHK$156.30+1.10%140.1B-236.82-HK$0.66N/A
1177.HKHK$7.32-2.66%130.9B61.00HK$0.12+0.96%
2269.HKHK$31.35-2.64%127.6B36.88HK$0.85N/A
1530.HKHK$30.20-5.92%71.3B32.47HK$0.93+0.83%
3759.HKHK$21.80-4.18%56.3B18.96HK$1.15+1.10%
6821.HKHK$101.70-4.69%40.8B32.91HK$3.09+1.18%
1877.HKHK$24.55-3.73%38.6B-17.29-HK$1.42N/A
9995.HKHK$58.65-2.74%38B-19.68-HK$2.98N/A
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2162.HK vs 1801.HK Comparison August 2025

2162.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2162.HK stands at 18.1B. In comparison, 1801.HK has a market cap of 159B. Regarding current trading prices, 2162.HK is priced at HK$61.55, while 1801.HK trades at HK$93.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2162.HK currently has a P/E ratio of -28.50, whereas 1801.HK's P/E ratio is -1328.57. In terms of profitability, 2162.HK's ROE is -0.20%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 2162.HK is less volatile compared to 1801.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2162.HK.Check 1801.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;